ABSTRACT
Breast cancer clinical treatment selection is based on the immunohistochemical determination of four proteins: ESR1, PGR, HER2, and MKI67. Our aim was to correlate immunohistochemical results to proteome-level technologies in measuring the expression of these markers. We also aimed to integrate available proteome-level breast cancer datasets to identify and validate new prognostic biomarker candidates.
We identified protein studies involving breast cancer patient cohorts with published survival and proteomic information. Immunohistochemistry and proteomic technologies were compared using the Mann-Whitney test. Receiver operating characteristics (ROC) curves were generated to validate discriminative power. Cox regression and Kaplan-Meier survival analysiss were calculated to assess prognostic power. The false discovery rate was computed to correct for multiple hypothesis testing.
The complete database contains protein expression data and survival information from four independent cohorts for 1,229 breast cancer patients. In all four studies combined, a total of 7,342 unique proteins were identified, and 1,417 of these were identified in at least three datasets. ESR1, PGR, HER2 protein expression levels determined by RPPA or LC-MS/MS methods showed a significant correlation with the levels determined by immunohistochemistry (p<0.0001). PGR and ESR1 levels showed a moderate correlation (correlation coefficient=0.17, p=0.0399). A panel of candidate proteins, including apoptosis-related proteins (BCL2,), adhesion markers (CDH1, CLDN3, CLDN7) and basal markers (cytokeratins), were validated as prognostic biomarkers. We expanded our established web tool to validate survival-associated biomarkers to include the proteomic datasets analyzed in this study (https://kmplot.com/analysis/).
Large proteomic studies now provide sufficient data enabling the validation and ranking of new protein biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study was supported by the 2018-2.1.17-TET-KR-00001, 2018-1.3.1-VKE-2018-00032 and KH-129581 grants of the National Research, Development and Innovation Office, Hungary. The use of the computational infrastructure of Pazmany Peter University, provided within the National Bionics Program, is gratefully acknowledged. The authors acknowledge the support of ELIXIR Hungary (www.elixir-hungary.org).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study did not need ethics committee approval.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data sharing is not applicable to this article as no new data were created or analyzed in this study, however, we expanded our established web tool to validate survival-associated biomarkers to include the proteomic datasets analyzed in this study (https://kmplot.com/analysis/).
